Kura Oncology reports Phase 1 data for ziftomenib: 30% CR, 35% CRc in R/R NPM1-m AML at RP2D

Kura Oncology, Inc.

In 20 NPM1-m R/R AML patients at 600mg RP2D: CR rate 30%, composite CR (CRc) 35%, ORR 40%.
Median duration of CRc response 8.2 months; median OS 5.1 months with 8.0 months follow-up.
Safety: 85% had Grade ≥3 TEAEs; differentiation syndrome (any grade) 20%, Grade 3 DS 5%.
Patients heavily pretreated: median 2.5 prior therapies, 60% prior venetoclax, 15% prior SCT.
Registration-directed Phase 2 study of ziftomenib monotherapy in R/R NPM1-m AML now accruing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.